Lupin Tarapur API facility gets 3 observations from USFDA
The inspection of the Tarapur facility was carried out by the US health regulator between September 16 to September 20, 2019, said Lupin.
Mumbai: Pharma major Lupin Limited (Lupin) has received 3 observations from the United States Food and Drug Administration (U.S. FDA) for its Tarapur manufacturing (API) facility.
The inspection of the facility was carried out by the US health regulator between September 16 to September 20, 2019. USFDA issues three observations after inspecting the facility.
Commenting on the same, Lupin said, " The Company is confident of addressing them satisfactorily."
Read Also: Lupin gets USFDA nod for a generic equivalent of UNITHROID to treat thyroid
Based in Mumbai, Lupin is a player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAI D space and holds a global leadership position in the AntiTB segment.
Read Also: Lupin gets USFDA warning letter for Mandideep Unit-1 facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd